Celldex Therapeutics reported $29.5M in Operating Expenses for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Abbvie ABBV:US USD 9.62B 590M
Agenus AGEN:US USD 88.08M 23.66M
Amgen AMGN:US USD 4.61B 695M
Aptinyx Inc APTX:US USD 14.66M 2.45M
Biocept BIOC:US USD 11.16M 4.54M
Bristol Myers Squibb BMY:US USD 9.46B 716M
Celldex Therapeutics CLDX:US USD 29.5M 1.4M
Cytrx CYTR:US USD 1.29M 7.73M
Glaxosmithkline GSK:US GBP 5.51B 1.13B
Immunogen IMGN:US USD 100.73M 7.92M
Merrimack Pharmaceuticals MACK:US USD 504K 18K
Nektar Therapeutics NKTR:US USD 74.49M 3.43M
Newlink Genetics NLNK:US USD 9.35M 1.3M
Northwest Biotherapeutics NWBO:US USD 16.28M 5.41M
Pfizer PFE:US USD 19.12B 5.9B
Rigel Pharmaceuticals RIGL:US USD 49.2M 8.39M
Roche Holding ROG:VX 25.06B 4.31B
Seattle Genetics SGEN:US USD 682.15M 20.95M